Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: Results of a multicentric prospective study at 12 months follow-up

Dermatology

Volumn 225, Issue 3, 2013, Pages 220-230

  Puig, Lluís ^a   Camacho Martínez, Francisco Miguel ^a   Gimeno Carpio, Enrique ^b   López Ávila, Angel ^c   García Calvo, Carmen ^d,e  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d Allergy Section   (Spain)

^e Hospital Santa Maria del Rosell ^*  (Spain)

Author keywords

Efficacy; Etanercept; Moderate to severe plaque psoriasis; Observational study; Routine clinical practice

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; CLINICAL PRACTICE; COLON CANCER; CONGESTIVE HEART FAILURE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; INJECTION SITE REACTION; JAUNDICE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MARGINAL LYMPHOMA; MUCOCUTANEOUS JAUNDICE; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RESPIRATORY TRACT INFECTION; SKIN DISEASE; SPAIN; TENOSYNOVITIS; THERAPY EFFECT; TUBERCULOSIS;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME;

EID: 84873077076     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000343605     Document Type: Article

References (33)

1. Ferrandiz C, Bordas X, Garcia-Patos V, Puig S, Pujol R, Smandia A: Prevalence of psoriasis in Spain (Epiderma Project: Phase I). J Eur Acad Dermatol Venereol 2001; 15: 20-23.
2. Lebwohl M: Psoriasis. Lancet 2003; 361: 1197-1204.
3. Papp KA: The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7-15.
4. Schotte H, Schluter B, Willeke P, Tidow N, Assmann G, Domschke W, Kekow J, Gaubitz M: Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 960-964.
5. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
6. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group: A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
7. Van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J: Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177-1185.
8. Strohal R, Puig L, Chouela E, Tsai TF, Melin J, Freundlich B, Molta CT, Fuiman J, Pedersen R, Robertson D: The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat DOI: 10.3109/09546634.2012.658015.
9. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A: Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-726.
10. Leonardi C, Strober B, Gottlieb AB, Elewski BE, Ortonne JP, van de Kerkhof P, Chiou CF, Dunn M, Jahreis A: Long-term safety and efficacy of etanercept in patients with psoriasis: An open-label study. J Drugs Dermatol 2010; 9: 928-937.
11. Papp KA, Poulin Y, Bissonnette R, Bourcier M, Toth D, Rosoph L, Poulin-Costello M, Setterfield M, Syrotuik J: Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2010; 66:e33-e45.
12. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group: Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241-251.
13. Paller AS, Siegfried EC, Eichenfield LF, Pariser D, Langley RG, Creamer K, Kricorian G: Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010; 63: 762-768.
14. Sterry W, Ortonne JP, Kirkham B, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340:c147.
15. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, Cuscito R: Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365-373.
16. Rivera R, García-Doval I, Carretero G, Daudén E, Sánchez-Carazo J, Ferrándiz C, Herrera E, Alsina M, Ferrán M, López-Estebaranz JL, Gómez F, Herranz JM, Carrascosa JM, Vanaclocha F, members of the BIOBADADERM group: BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: First report (in Spanish). Actas Dermosifiliogr 2011; 102: 132-141.
17. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG: TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann NY Acad Sci 2009; 1173: 837-846.
18. Esposito M, Giunta A, Mazzotta A, Babino G, Talamonti M, Chimenti MS, Chimenti S: Continuous treatment of plaque-type psoriasis with etanercept: An observational longterm experience. Int J Immunopathol Pharmacol 2010; 23: 503-509.
19. Barrera MV, Habicheyn S, Mendiola MV, Herrera Ceballos E: Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008; 18: 683-687.
20. Jiménez-Puya R, Gómez-Garcia F, Amorrich-Campos V, Moreno-Giménez JC: Etanercept: efficacy and safety. J Eur Acad Dermatol Venereol 2009; 23: 402-405.
21. Sánchez-Moya AI, Dauden E: Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: Report of a case series with 144 patients. J Eur Acad Dermatol Venereol 2011; 25: 730-733.
22. Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A: Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 2012; 26: 1331-1344.
23. Ortonne J-P, Griffiths C, Dauden E, Strohal R, Robertson D, Pedersen R, Molta CH, Freundlich B: Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: The CRYSTEL Study. Expert Rev Dermatol 2008; 3: 657-665.
24. Boehncke WH, Brasie RA, Barker J, Chimenti S, Daudén E, de Rie M, et al, European Dermatology Expert Group: Recommendations for the use of etanercept in psoriasis: A European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006; 20: 988-998.
25. Federman DG, Shelling M, Prodanovich S, Gunderson CG, Kirsner RS: Psoriasis: An opportunity to identify cardiovascular risk. Br J Dermatol 2009; 160: 1-7.
26. Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, Sato R, Boggs R: The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 2010; 24: 548-554.
27. Puig L: Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol 2011; 25: 1007-1011.
28. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM: Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-456.
29. Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, van de Kerkhof PC, Zitnik R, Nakanishi A, Jahreis A: Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. J Am Acad Dermatol 2006; 54:S92-S100.
30. Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tyring S, Papp KA, Li J, Baumgartner SW: Integrated safety analysis: Shortand long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2012; 67: 245-256.
31. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
32. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies Group: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894.
33. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, BSRBR Control Centre Consortium, Symmons DP, BSR Biologics Register: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-528.